CAS: 173529-46-9; (E)-4-(2-(N-((4-Methoxyphenyl)Sulfonyl)Acetamido)Styryl)Pyridine 1-Oxide

📜(Nz)-N-[(6E)-6-[2-(1-Hydroxypyridin-4-Ylidene)Ethylidene]Cyclohexa-2,4-Dien-1-Ylidene]-4-Methoxybenzenesulfonamide 反应生成(E)-4-[2-[2-[n-乙酰基-N-[(4-甲氧基苯基)磺酰]氨基]苯基]乙烯基]吡啶1-氧化物
参考文献:Aminostilbazole Derivative And Medicine
标题:Aminostilbazole Derivative And Medicine
摘要:本发明涉及以下公式或其水合物和盐的氨基苯乙烯衍生物.其中,R1和r2分别表示氢等;R3,R4,R13和r14分别表示氢,C1-3酰基,卤素,羟基等;R5表示氢或羟基取代的c1-3烷基等;R6表示苯磺酰取代的c1-3烷氧基等;环y表示苯环等;环z表示4-吡啶基,其氧化物等.该化合物可用于治疗各种恶性肿瘤.

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.